XML 23 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Average

​

​

​

Value of Initial Fixed $100

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Summary

​

Average

​

Investment Based on:

​

​

​

​

​

​

Summary

​

​

​

​

​

​

​

Compensation

​

Compensation

​

​

​

Peer Group

​

​

​

Net

​

​

Compensation

​

Compensation

​

Summary

​

​

​

Table Total for

​

Actually Paid

​

Total

​

Total

​

Net

​

Product

​

​

Table Total

​

Actually Paid

​

Compensation

​

Compensation

​

Non-PEO

​

to Non-PEO

​

Shareholder

​

Shareholder

​

Income

​

Revenue

​

​

for Dr. Dayno

​

to Dr. Dayno

​

Table Total for

​

Actually Paid

​

NEOs

​

NEOs

​

Return

​

Return

​

(in Thousands)

​

(in thousands)

Year

  ​ ​ ​

($)

  ​ ​ ​

($)(1)(2)

  ​ ​ ​

Mr. Jacobs

  ​ ​ ​

to Mr. Jacobs

  ​ ​ ​

($)

  ​ ​ ​

($)(1)(2)

  ​ ​ ​

($)

  ​ ​ ​

($)(3)

  ​ ​ ​

($)

  ​ ​ ​

(4)

2025

 

7,899,535

 

4,761,901

 

—

 

—

 

2,700,842

 

1,151,630

 

104

 

120

 

158,687

 

868,453

2024

 

7,145,170

 

7,678,134

 

—

 

—

 

3,340,360

 

3,986,190

 

93

 

103

 

145,493

 

714,734

2023

 

4,450,294

 

2,905,735

 

36,634

 

(5,020,055)

 

3,146,628

 

491,493

 

87

 

104

 

128,853

 

582,022

2022

 

—

 

—

 

514,752

 

2,943,454

 

748,069

 

3,061,521

 

149

 

100

 

181,468

 

437,855

2021

 

—

 

—

 

885,554

 

1,960,526

 

1,898,884

 

1,355,745

 

115

 

113

 

34,597

 

305,440

(1)Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:

​

​

​

​

​

​

Year

  ​ ​ ​

PEO

  ​ ​ ​

Non-PEO NEOs

2025

 

Jeffrey M. Dayno, M.D.

 

Sandip Kapadia, Adam Zaeske, Jeffrey Dierks, Kumar Budur and Andrew Serafin

2024

 

Jeffrey M. Dayno, M.D.

 

Sandip Kapadia, Jeffrey Dierks, Kumar Budur and Andrew Serafin

2023

 

Jeffrey M. Dayno, M.D., John C. Jacobs

 

Sandip Kapadia, Jeffrey Dierks, Kumar Budur and Andrew Serafin

2022

 

John C. Jacobs

 

Sandip Kapadia, Jeffrey M. Dayno, M.D., Jeffrey Dierks, and Andrew Serafin

2021

 

John C. Jacobs

 

Sandip Kapadia, Jeffrey M. Dayno, M.D., Jeffrey Dierks, Andrew Serafin and Susan Drexler

​

​

​

​

​

​

​

​

​

​

​

​

​

Compensation actually paid to our NEOs represents the “Total” compensation reported in the Summary Compensation Table for the 2025 fiscal year, as adjusted as follows:

​

​

​

​

​

​

​

​

​

Average Non- 

Adjustments

  ​ ​ ​

PEO

  ​ ​ ​

PEO NEOs

Deduction for Amounts Reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table for Applicable FY

 

(6,575,521)

 

(1,906,907)

Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End

 

5,347,555

 

1,466,164

Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date

 

—

 

—

Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End

 

(659,274)

 

(47,891)

Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date

 

(1,250,394)

 

(558,642)

Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End

 

—

 

(501,936)

Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date

 

—

 

—

Increase based on Incremental Fair Value of Options/SARs Modified during Applicable FY

 

—

 

—

Deduction for Change in the Actuarial Present Values reported under the “Change in Pension Value and Nonqualified Deferred Compensation Earnings” Column of the Summary Compensation Table for Applicable FY

 

—

 

—

Increase for Service Cost and, if applicable, Prior Service Cost for Pension Plans

 

—

 

—

TOTAL ADJUSTMENTS

 

(3,137,634)

 

(1,549,212)

​

(2)Fair value or change in fair value, as applicable, of equity awards in the “Compensation Actually Paid” columns was determined by reference to (i) for solely service-vesting RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); and (ii) for stock options, a Black-Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life equal to the lesser of the original expected life utilizing the simplified method or remaining life at each revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. We provide information regarding the assumptions used to calculate the valuation of the award in Note 15 to the consolidated financial statements included in the Annual Report on Form 10-K filed on February 24, 2026.
(3)For the relevant fiscal year, represents the cumulative TSR (the “Peer Group TSR”) of the NASDAQ Biotechnology Index, which is the same peer group used in Part II, Item 5 of our Form 10-K.
(4)Net Product Revenue is a GAAP measure reported in the Company’s consolidated statements of operations and comprehensive income (loss).
        
Company Selected Measure Name Net Product Revenue        
Named Executive Officers, Footnote
(1)Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:

​

​

​

​

​

​

Year

  ​ ​ ​

PEO

  ​ ​ ​

Non-PEO NEOs

2025

 

Jeffrey M. Dayno, M.D.

 

Sandip Kapadia, Adam Zaeske, Jeffrey Dierks, Kumar Budur and Andrew Serafin

2024

 

Jeffrey M. Dayno, M.D.

 

Sandip Kapadia, Jeffrey Dierks, Kumar Budur and Andrew Serafin

2023

 

Jeffrey M. Dayno, M.D., John C. Jacobs

 

Sandip Kapadia, Jeffrey Dierks, Kumar Budur and Andrew Serafin

2022

 

John C. Jacobs

 

Sandip Kapadia, Jeffrey M. Dayno, M.D., Jeffrey Dierks, and Andrew Serafin

2021

 

John C. Jacobs

 

Sandip Kapadia, Jeffrey M. Dayno, M.D., Jeffrey Dierks, Andrew Serafin and Susan Drexler

        
Peer Group Issuers, Footnote
(3)For the relevant fiscal year, represents the cumulative TSR (the “Peer Group TSR”) of the NASDAQ Biotechnology Index, which is the same peer group used in Part II, Item 5 of our Form 10-K.
        
Adjustment To PEO Compensation, Footnote

​

​

​

​

​

​

​

​

​

​

​

Compensation actually paid to our NEOs represents the “Total” compensation reported in the Summary Compensation Table for the 2025 fiscal year, as adjusted as follows:

​

​

​

​

​

​

​

​

​

Average Non- 

Adjustments

  ​ ​ ​

PEO

  ​ ​ ​

PEO NEOs

Deduction for Amounts Reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table for Applicable FY

 

(6,575,521)

 

(1,906,907)

Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End

 

5,347,555

 

1,466,164

Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date

 

—

 

—

Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End

 

(659,274)

 

(47,891)

Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date

 

(1,250,394)

 

(558,642)

Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End

 

—

 

(501,936)

Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date

 

—

 

—

Increase based on Incremental Fair Value of Options/SARs Modified during Applicable FY

 

—

 

—

Deduction for Change in the Actuarial Present Values reported under the “Change in Pension Value and Nonqualified Deferred Compensation Earnings” Column of the Summary Compensation Table for Applicable FY

 

—

 

—

Increase for Service Cost and, if applicable, Prior Service Cost for Pension Plans

 

—

 

—

TOTAL ADJUSTMENTS

 

(3,137,634)

 

(1,549,212)

        
Non-PEO NEO Average Total Compensation Amount $ 2,700,842 $ 3,340,360 $ 3,146,628 $ 748,069 $ 1,898,884
Non-PEO NEO Average Compensation Actually Paid Amount $ 1,151,630 3,986,190 491,493 3,061,521 1,355,745
Adjustment to Non-PEO NEO Compensation Footnote

​

​

​

​

​

​

​

​

​

​

​

Compensation actually paid to our NEOs represents the “Total” compensation reported in the Summary Compensation Table for the 2025 fiscal year, as adjusted as follows:

​

​

​

​

​

​

​

​

​

Average Non- 

Adjustments

  ​ ​ ​

PEO

  ​ ​ ​

PEO NEOs

Deduction for Amounts Reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table for Applicable FY

 

(6,575,521)

 

(1,906,907)

Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End

 

5,347,555

 

1,466,164

Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date

 

—

 

—

Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End

 

(659,274)

 

(47,891)

Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date

 

(1,250,394)

 

(558,642)

Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End

 

—

 

(501,936)

Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date

 

—

 

—

Increase based on Incremental Fair Value of Options/SARs Modified during Applicable FY

 

—

 

—

Deduction for Change in the Actuarial Present Values reported under the “Change in Pension Value and Nonqualified Deferred Compensation Earnings” Column of the Summary Compensation Table for Applicable FY

 

—

 

—

Increase for Service Cost and, if applicable, Prior Service Cost for Pension Plans

 

—

 

—

TOTAL ADJUSTMENTS

 

(3,137,634)

 

(1,549,212)

        
Equity Valuation Assumption Difference, Footnote
(2)Fair value or change in fair value, as applicable, of equity awards in the “Compensation Actually Paid” columns was determined by reference to (i) for solely service-vesting RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); and (ii) for stock options, a Black-Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life equal to the lesser of the original expected life utilizing the simplified method or remaining life at each revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. We provide information regarding the assumptions used to calculate the valuation of the award in Note 15 to the consolidated financial statements included in the Annual Report on Form 10-K filed on February 24, 2026.
        
Compensation Actually Paid vs. Total Shareholder Return

Graphic

​

        
Compensation Actually Paid vs. Net Income

Graphic

​

        
Compensation Actually Paid vs. Company Selected Measure

Graphic

​

        
Tabular List, Table

 Pay Versus Performance Tabular List

We believe the following performance measure represents the most important financial performance measure used by us to link compensation actually paid to our NEOs for the fiscal year ended December 31, 2025:

·

Net Product Revenue.

For additional details regarding our most important financial performance measures, please see the section entitled “Cash Incentive Compensation” in the CD&A above.

        
Total Shareholder Return Amount $ 104 93 87 149 115
Peer Group Total Shareholder Return Amount 120 103 104 100 113
Net Income (Loss) $ 158,687,000 $ 145,493,000 $ 128,853,000 $ 181,468,000 $ 34,597,000
Company Selected Measure Amount 868,453,000 714,734,000 582,022,000 437,855,000 305,440,000
PEO Name Jeffrey M. Dayno        
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00%        
Measure:: 1          
Pay vs Performance Disclosure          
Name Net Product Revenue        
Jeffrey M. Dayno          
Pay vs Performance Disclosure          
PEO Total Compensation Amount $ 7,899,535 $ 7,145,170 $ 4,450,294    
PEO Actually Paid Compensation Amount 4,761,901 $ 7,678,134 2,905,735    
John C. Jacobs          
Pay vs Performance Disclosure          
PEO Total Compensation Amount     36,634 $ 514,752 $ 885,554
PEO Actually Paid Compensation Amount     $ (5,020,055) $ 2,943,454 $ 1,960,526
PEO | Jeffrey M. Dayno          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (3,137,634)        
PEO | Jeffrey M. Dayno | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (6,575,521)        
PEO | Jeffrey M. Dayno | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 5,347,555        
PEO | Jeffrey M. Dayno | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (659,274)        
PEO | Jeffrey M. Dayno | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,250,394)        
Non-PEO NEO          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,549,212)        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,906,907)        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,466,164        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (47,891)        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (558,642)        
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (501,936)